P. F. Halloran, Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, pp.2715-2744, 2004.

B. D. Myers, R. Sibley, L. Newton, S. J. Tomlanovich, C. Boshkos et al., The long-term course of cyclosporineassociated chronic nephropathy, Kidney Int, vol.33, pp.590-600, 1988.

A. O. Ojo, P. J. Held, F. K. Port, R. A. Wolfe, A. B. Leichtman et al., Chronic renal failure after transplantation of a nonrenal organ, N Engl J Med, vol.349, pp.931-971, 2003.

K. Krejci, T. Tichy, M. Hruby, P. Horak, H. Ciferska et al., Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage

, Transpl Int, vol.23, pp.364-73, 2010.

M. Hu, Y. M. Wang, Y. Wang, G. Y. Zhang, G. Zheng et al., Regulatory T Cells in kidney disease and transplantation, Kidney Int, vol.90, pp.502-516, 2016.

N. Kamar, D. Bello, A. Belliere, J. Rostaing, and L. , Calcineurin inhibitor-sparing regimens based on mycophenolate acid after kidney transplantation, Transpl Int, vol.28, pp.928-931, 2015.

M. R. Weir, S. Blahut, C. Drachenburg, C. Young, J. Papademitriou et al., Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function, Am J Nephrol, vol.24, pp.379-86, 2004.

C. Dudley, E. Pohanka, H. Riad, J. Dedochova, P. Wijngaard et al.,

, Mycophenolate mofetil substitution for cyclosporine in renal transplant recipients with chronic progressive allograft dysfunction : the « creeping creatinine study, Transplantation, vol.79, pp.466-75, 2005.

L. Frimat, E. Cassuto-viguier, F. Provôt, L. Rostaing, B. Charpentier et al.,

M. Kessler, Long-term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction : REFERENCE study 3-year follow up, J Transplant, 2010.

D. Abramowicz, D. Manas, M. Lao, Y. Vanrenterghem, D. Castillo et al., Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study, Transplantation, vol.74, pp.1725-1759, 2002.

I. Etienne, O. Toupance, J. Bénichou, A. Thierry, A. Najjar et al., 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits

, Nephrol Dial Transplant, vol.25, pp.3096-106, 2010.

V. R. Peddi, A. Wiseman, K. Chavin, and D. Slakey, Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation, Transplant Rev, vol.27, pp.97-107, 2013.

L. Rostaing, P. Massari, V. D. Garcia, E. Mancilla-urrea, G. Nainan et al., Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients : a randomized phase II study, Clin J Am Soc Nephrol, vol.6, pp.430-439, 2011.

J. Grinyo, J. Alberu, F. L. Contieri, R. C. Manfro, G. Mondragon et al., Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-years results from the long-term extension of a phase II study, Transplant Int, vol.25, pp.1059-64, 2012.

H. T. Tran, M. K. Acharya, D. B. Mckay, M. H. Sayegh, C. B. Carpentier et al., Avoidance of cyclosporine in renal transplantation : effects of daclizumab, mycophenolate mofetil, and steroids, J Am Soc Nephrol, vol.11, pp.1903-1912, 2000.

M. Guba, M. Rentsch, C. D. Wimmer, A. Uemeksuez, W. D. Illner et al., Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil, Transplant Int, vol.21, pp.637-682, 2008.

H. Ekberg, J. Grinyo, B. Nashan, Y. Vanrenterghem, F. Vicenti et al., Cyclosporine sparing with mycophenolate mofetil daclizumab and corticosteroids in renal allograft recipients : the CAESAR study, Am J Transplant, vol.7, pp.560-70, 2007.

H. Ekberg, H. Tedesco-silva, A. Demirbas, S. Vitko, B. Nashan et al.,

, N Engl J Med, vol.35, pp.2562-75, 2007.

S. M. Flechner, S. M. Kurian, K. Solez, D. J. Cook, J. T. Burke et al., De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years, Am J Transplant, vol.4, pp.1776-85, 2004.

S. M. Flechner, M. Glyda, S. Cockfield, J. Grinyo, L. Ch et al., The ORION study: comparison of two sirolimus based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients, Am J Transplant, vol.11, pp.1633-1677, 2011.

K. Budde, T. Becker, W. Aros, C. Sommerer, P. Reinke et al., Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial, Lancet, vol.377, pp.837-884, 2011.

Y. Lebranchu, A. Thierry, O. Toupance, P. F. Westeel, E. I. Thervet et al., Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation : concept study, Am J Transplant, 2009.

A. Durrbach, J. M. Pestana, T. Pearson, F. Vincenti, V. D. Garcia et al., A phase III study of belatacept versus cyclosphorine in kidney transplants from extended criteria donors (BENEFIT-EXT study), Am J Transplant, vol.10, pp.547-57, 2010.

F. Vincenti, C. P. Larsen, J. Alberu, B. Bresnahan, V. D. Garcia et al., Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients, Am J Transplant, vol.12, pp.210-217, 2012.

R. Snanoudj, C. Tinel, and C. Legendre, Immunological risks of minimization strategies, Transplant Int, vol.28, pp.901-911, 2015.

J. Moore, L. Middleton, P. Cockwell, D. Adu, S. Ball et al., Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis, Transplantation, vol.87, pp.591-605, 2009.

A. Sharif, S. Shabir, S. Chand, P. Cockwell, S. Ball et al., Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation, J Am Soc Nephrol, vol.22, pp.2107-2125, 2011.

D. Sawinski, J. Trofe-clark, B. Leas, S. Uhl, S. Tuteja et al., Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-Analysis

, Am J Transplant, vol.16, pp.2117-2155, 2016.

E. Pouliquen, A. Koenig, C. C. Chen, A. Sicard, M. Rabeyrin et al., Recent advances in renal transplantation: antibody-mediated rejection takes center stage, Rep, vol.12, pp.7-51, 2015.

J. E. Cooper, J. Gralla, L. Cagle, R. Goldberg, L. Chan et al., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes, Transplantation, vol.91, pp.1103-1112, 2011.

J. E. Worthington, S. Martin, A. -. Husseini, D. M. Dyer, P. A. Johnson et al., Posttranspantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome, Transplantation, vol.75, pp.1034-1074, 2003.

N. Lachmann, P. I. Terasaki, K. Budde, L. Liefeldt, A. Kahl et al., Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts, Transplantation, vol.87, pp.1505-1518, 2009.

P. I. Terasaki and M. Ozawa, Prediction kidney graft failure by HLA antibodies: a prospective trial, Am J Transplant, vol.4, pp.438-481, 2004.

P. C. Lee, L. Zhu, P. I. Terasaki, and M. J. Everly, HLA specific antibodies developed in the first year posttransplant are predicitve of chronic rejection and renal graft loss, Transplantation, vol.88, pp.568-74, 2009.

J. M. Devos, A. O. Gaber, L. D. Teeter, E. A. Graviss, S. J. Patel et al., Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection, Transplantation, vol.97, pp.534-574, 2014.

J. Zheng, X. Xue-w-jing, J. Hou, X. Tian, P. Tian et al., Influence of de novo donor-specific antibody on early renal allograft function recovery, Ren Fail, vol.37, pp.462-470, 2015.

G. Einecke, B. Sis, J. Reeve, M. Mengel, P. M. Campbell et al., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure, Am J Transplant, vol.9, pp.2520-2551, 2009.

C. Lefaucheur, D. Viglietti, C. Bentlejewski, J. P. Duong-van-huyen, D. Vernerey et al., IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury

, J Am Soc Nephrol, vol.27, pp.293-304, 2016.

A. Loupy, C. Lefaucheur, D. Vernerey, C. Prugger, J. P. Duong-van-huyen et al., Complement-binding anti-HLA antibodies and kidney-allograft survival, N Engl J Med, vol.369, pp.1215-1241, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02325503

G. Guidicelli, F. Guerville, S. Lepreux, C. Wiebe, O. Thaunat et al., Non complement-binding de novo donor-specific anti HLA antibodies and kidney allograft survival, J Am Soc Nephrol, vol.27, pp.615-640, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01953712

M. Haas, R. A. Montgomery, D. L. Segev, M. H. Rahman, L. C. Racusen et al., Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts, Am J Transplant, vol.7, pp.576-85, 2007.

B. Sis, G. S. Jhangri, S. Bunnag, K. Allanach, B. Kaplan et al., Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4D staining, Am J Transplant, vol.9, pp.2312-2335, 2009.

R. B. Colvin, Antibody-mediated renal allograft rejection : diagnosis and pathogenesis, J Am Soc Nephrol, vol.18, pp.1046-56, 2007.

A. Loupy, C. Suberbielle-boissel, G. S. Hill, C. Lefaucheur, D. Anglicheau et al., Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies, Am J Transplant, vol.9, pp.256-70, 2009.

C. Wiebe, I. W. Gibson, T. D. Blydt-hansen, M. Karpinski, J. Ho et al., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant, Am J Transplant, vol.12, pp.1157-67, 2012.

J. M. Chemouny, C. Suberbielle, M. Rabant, J. Zuber, M. A. Alyanakian et al., De novo donor specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection, Transplantation, vol.99, pp.965-72, 2015.

C. Lefaucheur, A. Loupy, D. Vernerey, J. P. Duong-van-huyen, C. Suberbielle et al., Antibody-mediated vascular rejection of kidney allografts: a population-based study, Lancet, vol.381, pp.313-322, 2013.

G. S. Hill, D. Nochy, P. Bruneval, J. P. Duong-ven-huyen, D. Glotz et al., Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation, J Am Soc Nephrol, vol.22, pp.975-83, 2011.

E. Perbos, E. Juinier, G. Guidicelli, C. Dromer, P. Billes et al., Evolution of donor specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors, Clin Transplant, vol.28, pp.1054-60, 2014.

L. Liefeldt, S. Brakemeier, P. Glander, J. Waiser, N. Lachmann et al., Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation, Am J Transplant, vol.12, pp.1192-1200, 2012.

Z. M. El-zoghby, M. D. Stegall, D. J. Lager, W. K. Kremers, H. Amer et al., Identifying specific causes of kidney allograft loss, Am J Transplant, vol.9, pp.527-562, 2009.

M. Oellerich, V. W. Armstrong, E. Schütz, and L. M. Shaw, Therapeutic drug monitoring of cyclosporine and tacrolimus, Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus, vol.31, pp.309-325, 1998.

J. Schiff, E. Cole, and M. Cantarovich, Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist, Clin J Am Soc Nephrol, vol.2, pp.374-384, 2007.

B. D. Tait, C. Susal, H. M. Gebel, P. W. Nickerson, A. A. Zachary et al., Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation, Transplantation, vol.95, pp.19-47, 2013.

M. J. Everly, L. M. Rebellato, C. E. Haisch, M. Ozawa, K. Parker et al., Incidence and impact of de novo donor-specific alloantibody in primary renal allografts, Transplantation, vol.95, pp.410-417, 2013.

B. H. Shin, S. Ge, J. Mirocha, A. Karasyov, A. Vo et al., Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents, Tranplantation, vol.97, pp.294-300, 2014.

H. Kaneku, O. Leary, J. G. Banuelos, N. Jennings, L. W. Susskind et al., De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients, Am J Transplant, vol.13, pp.1541-1549, 2013.

D. Sawinski, K. A. Forde, J. Trofe-clark, P. Patel, B. Olivera et al., Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies, J Am Soc Nephrol, vol.26, pp.966-975, 2015.

S. Baid, N. Tolkoff-rubin, S. Saidman, R. Chung, W. W. Williams et al., Acute humoral rejection in hepatitis Cinfected renal transplant recipients receiving entiviral therapy, Am J Transplant, vol.3, pp.74-82, 2003.

O. Leary, J. G. Samaniego, M. Barrio, M. C. Potena, L. Zeevi et al., The influence of Immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients, Transplantation, vol.100, pp.39-53, 2016.

M. Deters, V. Kaever, and G. I. Kirchner, Liquid Chromatography/Mass Spectrometry For Therapeutic Drug Monitoring of Immunosuppressants, Analytica Chimica Acta, vol.492, pp.133-178, 2003.

, Tableau 2 (suite) Total (n=247) Non Minimisés Minimisés Néphropathie initiale 0, p.27

, Glomérulonephrite chronique (hors vascularite) 63 (25,5%) 21 (25,6%) 42 (25,5%)

, Type de donneur 0, p.8

, Décédé-critères élargis, vol.63, p.9

. Décédé,

, HTA : Hypertension artérielle ; AVC : Accident vasculaire cérébral ; AOMI : Artériopathie Oblitérante des Membres inférieurs

, VIH : Virus d'immunodéficience humaine ; BPCO : Bronchopneumopathie chronique obstructive ; SAL : Sérum anti-lymphocytaire